FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556282014> ?p ?o ?g. }

• W2556282014 abstract "Abstract Introduction: Small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) are viewed as similar entities by the World Health Organization. Patients with SLL are usually treated on protocols for indolent lymphomas, although the biology of SLL differs from that of follicular lymphomas. The purpose of this study was to assess differences, if any, in presenting characteristics, cytogenetics, treatment outcomes, and factors predicting survival between patients with CLL and those with absolute lymphocyte counts &lt;5,000 (SLL). Methods: An electronic database search of patients with CLL/SLL who presented at The University of Texas M.D. Anderson Cancer Center Department of Leukemia between 1985 and 2005 was performed. Results: Among 2,051 patients with untreated CLL/SLL, 199 patients had SLL and 1852 patients had CLL. Patients with SLL were referred for node enlargement (33%), coincidental abnormal white blood cell counts (27%), fatigue (11%), B-symptoms (10%), bruising/low platelets (8%), surgical specimens (8%), and other reasons (8%). In univariate analysis, patients with SLL had higher hemoglobin levels (p&lt;0.001), lower IgA and IgM immunoglobulin levels (p=0.03 and p=0.01, respectively), and lower rates of bone marrow lymphocytic infiltration (p&lt;0.001) than those with CLL. Age, sex, Binet stage, and β2-microglobulin levels were similar between the two groups. Fluorescence in situ hybridization (FISH) abnormalities were more frequent in tested patients with CLL compared with SLL patients (70% and 45%, respectively). Among 40 SLL patients with FISH abnormalities, 18% had 11q-, 25% had trisomy 12, 33% had 13q-, and 5% had 17p- abnormalities. Among 314 CLL patients with FISH abnormalities, 14% had 11q-, 16% had trisomy 12, 51% had 13q-, and 5% had 17p- abnormalities. Forty percent of patients with SLL and 49% of CLL patients required therapy after a median follow-up of 5.8 and 3.0 years, respectively (p&lt;0.001). Among evaluable patients (SLL, 32; CLL, 710), the overall response rates to various therapies were 78% (CR, 41%) and 88% (CR, 48%), respectively. Responses were more frequent among SLL patients treated with fludarabine, mitoxantrone, and dexamethasone (FND), FND with rituximab (R-FND) or fludarabine, cyclophosphamide, and rituximab (FCR) and among patients with CLL treated with FCR. In multivariate analysis of all 2,051 SLL/CLL patients, factors predicting longer survival were younger age (p&lt;0.0001), lower β2-microglobulin levels (p&lt;0.0001), lower alkaline phosphatase levels (p&lt;0.0001), higher hemoglobin levels (p&lt;0.0001), smaller number of nodal sites (p&lt;0.001), and lower lactate dehydrogenase levels (p=0.01); the absolute lymphocyte count was not a significant factor in survival (p=0.30). Conclusions: The presentation, cytogenetic abnormalities, and clinical outcome of SLL are similar but not identical to those of CLL. Our results suggest that SLL and CLL can be treated similarly. Regimens that include rituximab and a nucleoside analog, such as FCR or R-FND, are highly effective. Further characterization of SLL by genetic analysis is needed. Common response criteria should be standardized for both CLL and SLL, including the disappearance of radiologic and hematologic evidence of disease." @default.
• W2556282014 created "2016-11-30" @default.
• W2556282014 creator A5006104041 @default.
• W2556282014 creator A5027575595 @default.
• W2556282014 creator A5028845635 @default.
• W2556282014 creator A5034301588 @default.
• W2556282014 creator A5035410664 @default.
• W2556282014 creator A5047487417 @default.
• W2556282014 creator A5089428686 @default.
• W2556282014 creator A5090435894 @default.
• W2556282014 date "2005-11-16" @default.
• W2556282014 modified "2023-10-12" @default.
• W2556282014 title "Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia The M.D Anderson Cancer Center Experience." @default.
• W2556282014 doi "https://doi.org/10.1182/blood.v106.11.921.921" @default.
• W2556282014 hasPublicationYear "2005" @default.
• W2556282014 type Work @default.
• W2556282014 sameAs 2556282014 @default.
• W2556282014 citedByCount "1" @default.
• W2556282014 crossrefType "journal-article" @default.
• W2556282014 hasAuthorship W2556282014A5006104041 @default.
• W2556282014 hasAuthorship W2556282014A5027575595 @default.
• W2556282014 hasAuthorship W2556282014A5028845635 @default.
• W2556282014 hasAuthorship W2556282014A5034301588 @default.
• W2556282014 hasAuthorship W2556282014A5035410664 @default.
• W2556282014 hasAuthorship W2556282014A5047487417 @default.
• W2556282014 hasAuthorship W2556282014A5089428686 @default.
• W2556282014 hasAuthorship W2556282014A5090435894 @default.
• W2556282014 hasConcept C121608353 @default.
• W2556282014 hasConcept C126322002 @default.
• W2556282014 hasConcept C143998085 @default.
• W2556282014 hasConcept C144301174 @default.
• W2556282014 hasConcept C203014093 @default.
• W2556282014 hasConcept C2777058707 @default.
• W2556282014 hasConcept C2777938653 @default.
• W2556282014 hasConcept C2778461978 @default.
• W2556282014 hasConcept C2779338263 @default.
• W2556282014 hasConcept C2780653079 @default.
• W2556282014 hasConcept C38180746 @default.
• W2556282014 hasConcept C71924100 @default.
• W2556282014 hasConcept C90924648 @default.
• W2556282014 hasConceptScore W2556282014C121608353 @default.
• W2556282014 hasConceptScore W2556282014C126322002 @default.
• W2556282014 hasConceptScore W2556282014C143998085 @default.
• W2556282014 hasConceptScore W2556282014C144301174 @default.
• W2556282014 hasConceptScore W2556282014C203014093 @default.
• W2556282014 hasConceptScore W2556282014C2777058707 @default.
• W2556282014 hasConceptScore W2556282014C2777938653 @default.
• W2556282014 hasConceptScore W2556282014C2778461978 @default.
• W2556282014 hasConceptScore W2556282014C2779338263 @default.
• W2556282014 hasConceptScore W2556282014C2780653079 @default.
• W2556282014 hasConceptScore W2556282014C38180746 @default.
• W2556282014 hasConceptScore W2556282014C71924100 @default.
• W2556282014 hasConceptScore W2556282014C90924648 @default.
• W2556282014 hasLocation W25562820141 @default.
• W2556282014 hasOpenAccess W2556282014 @default.
• W2556282014 hasPrimaryLocation W25562820141 @default.
• W2556282014 hasRelatedWork W1988877261 @default.
• W2556282014 hasRelatedWork W2126137725 @default.
• W2556282014 hasRelatedWork W2140326973 @default.
• W2556282014 hasRelatedWork W2152182743 @default.
• W2556282014 hasRelatedWork W2557989823 @default.
• W2556282014 hasRelatedWork W2780314677 @default.
• W2556282014 hasRelatedWork W2805093224 @default.
• W2556282014 hasRelatedWork W2946317318 @default.
• W2556282014 hasRelatedWork W3200426900 @default.
• W2556282014 hasRelatedWork W74504067 @default.
• W2556282014 isParatext "false" @default.
• W2556282014 isRetracted "false" @default.
• W2556282014 magId "2556282014" @default.
• W2556282014 workType "article" @default.